Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

    Research output: Contribution to journalArticlepeer-review

    Abstract

    In this paper the clinical value of PET for early prediction of tumor response to Erlotinib in patients with advanced or metastatic nonsmall cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).
    Original languageEnglish
    Number of pages0
    JournalTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria'. Together they form a unique fingerprint.

    Cite this